Otsuka Ties Up With Mylan To Advance MDR-TB Drug In India?
Otsuka, which has been under fire over delayed access to delamanid in India, appears to have allied with Mylan, which has now secured a key clearance for the novel multidrug-resistant TB therapy in the country.
You may also be interested in...
Manufacturing plans for multidrug-resistant tuberculosis (MDR-TB) drug Deltyba (delamanid) in India appear to be gathering steam, with partners Otsuka and Mylan commencing the technology transfer process for the product, although activists are concerned about the broader contours of the arrangement. Deltyba is also expected to be used in children and adolescents in India.
Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses.
Johnson & Johnson’s tuberculosis R&D partnership with the Institute of Microbial Technology in India aims to develop shorter, simpler and safer TB regimens. The alliance has, at its forefront, an expert from the team that developed Sirturo (bedaquiline).